Pre-made Lulizumab benchmark antibody ( Single Domain Variable Fragment;L, anti-CD28 therapeutic antibody, Anti-Tp44 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lulizumab pegol (INN; development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. This drug was developed by Bristol-Myers Squibb.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-326-1mg	1mg	3090
GMP-Bios-ab-326-10mg	10mg	Inquiry
GMP-Bios-ab-326-100mg	100mg	Inquiry
GMP-Bios-ab-326-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody
INN Name	Lulizumab
Target	CD28
Format	Single Domain Variable Fragment;L
Derivation
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Bristol-Myers Squibb
Conditions Approved	na
Conditions Active	Sjogren's syndrome;Systemic lupus erythematosus;Renal transplant rejection
Conditions Discontinued	na
Development Tech	na